Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. May 14, 2008; 14(18): 2851-2857
Published online May 14, 2008. doi: 10.3748/wjg.14.2851
Published online May 14, 2008. doi: 10.3748/wjg.14.2851
Table 1 Basal and demographic data
Data | Group A Mesalamine + NAC (n = 19) | Group B Mesalamine + placebo (n = 18) | Total (n = 37) |
Age (mean ± SD) | 51.4 ± 14 | 42.2 ± 13 | 46.9 ± 14 |
White race, n (%) | 11 (57.8) | 13 (72.2) | 24 (64.8) |
Smoker, n (%) | 2 (10.5) | 3 (16.7) | 5 (13.5) |
Male, n (%) | 8 (42.1) | 5 (27.8) | 13 (35.1) |
Basal modified Truelove-Witts severity index (mean ± SD) | 5.95 ± 2.22 | 4.61 ± 2.09 | 5.30 ± 2.20 |
Table 2 Changes in disease activity assessed using modified Truelove-Witts Severity Index (mean ± SD) in subjects who received the drugs for 2 wk and 4 wk
Week of treatment | 0 | 2 | 4 | ANOVA statistical test (number of patients) |
Group A mesalamine plus NAC | 5.95 ± 2.22 | 4.68 ± 3.40 | 3.32 ± 3.71a | P = 0.046 (n = 19) |
Group B mesalamine plus placebo | 4.61 ± 2.09 | 4.17 ± 3.85 | 3.72 ± 3.91 | P = 0.735 (n = 18) |
Table 3 Hematological parameters
Group A | Group B | |||
Basal | 4 wk | Basal | 4 wk | |
Haemoglobin (g/100 mL) | 14.28 | 13.98 | 13.81 | 13.79 |
Haematocrit (g/100 mL) | 42.55 | 42.01 | 40.50 | 40.61 |
Erythrocytes (× 106/mm3) | 4.81 | 4.69 | 4.60 | 4.58 |
Platelet count (× 103/mm3) | 232.95 | 249.84 | 263.22 | 260.50 |
VSG (mm/h) | 17.13 | 15.00 | 19.60 | 17.38 |
Leukocytes (× 103/mm3) | 7.14 | 7.06 | 7.86 | 7.90 |
Neutrophils (%) | 62.63 | 61.45 | 63.75 | 58.61 |
Eosinophils (%) | 2.56 | 3.34 | 3.81 | 3.22 |
Basophils (%) | 0.32 | 0.55 | 0.44 | 0.22 |
Lymphocytes (%) | 25.89 | 28.03 | 27.82 | 27.74 |
Monocytes (%) | 6.97 | 7.20 | 7.14 | 7.88 |
Table 4 Biochemical parameters
Group A | Group B | |||
Basal | 4 wk | Basal | 4 wk | |
SGOT (units/L) | 16.89 | 16.47 | 20.47 | 25.06 |
SGPT (units/L) | 15.58 | 17.53 | 36.94 | 43.59 |
Phosphatase alkaline (units/L) | 93.56 | 86.61 | 93.59 | 86.71 |
Bilirubin (mg/100 mL) | 0.68 | 0.67 | 0.50 | 0.51 |
LDH (units/L) | 258.22 | 265.45 | 307.63 | 299.30 |
Serum creatinine (mg/100 mL) | 0.95 | 0.95 | 0.90 | 0.93 |
Urea/BUN (mg/100 mL) | 35.23 | 34.64 | 35.90 | 33.75 |
Total Proteins (g/100 mL) | 7.17 | 7.06 | 7.18 | 7.08 |
Albumin (g/100 mL) | 4.16 | 4.11 | 4.13 | 4.12 |
Na+ (mmol/L | 138.10 | 139.20 | 138.11 | 139.10 |
K+ (mmol/L) | 4.17 | 4.24 | 4.34 | 4.28 |
Glucose (mg/100 mL) | 91.53 | 89.54 | 83.53 | 85.88 |
Iron (&mgr;g/dL) | 70.27 | 69.00 | 78.56 | 84.82 |
Orosomucoid (mg/100 mL) | 85.19 | 90.98 | 98.06 | 89.98 |
CRP (mg/L) | 5.37 | 4.27 | 5.20 | 4.85 |
- Citation: Guijarro LG, Mate J, Gisbert JP, Perez-Calle JL, Marín-Jimenez I, Arriaza E, Olleros T, Delgado M, Castillejo MS, Prieto-Merino D, Lara VG, Peña AS. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: Randomized, placebo-controlled pilot study. World J Gastroenterol 2008; 14(18): 2851-2857
- URL: https://www.wjgnet.com/1007-9327/full/v14/i18/2851.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.2851